🔑 Key Takeaways
- The Indonesian Food and Drug Authority (BPOM) confirms that the national supply of pharmaceutical raw materials remains secure in 2026, despite potential disruptions to vital maritime routes in the Strait of Hormuz.
- Supply resilience strategies include diversifying import sources, boosting domestic production capacity for raw materials, and strengthening strategic reserves.
- The Indonesian government, through BPOM and relevant ministries, continues to invest in pharmaceutical self-sufficiency to reduce significant import dependency.
Jakarta, September 12, 2026 – Amidst renewed global geopolitical tensions highlighting the vulnerabilities of international supply chains, the Indonesian Food and Drug Authority (BPOM) reassures the public that the availability of Active Pharmaceutical Ingredients (APIs) in the country remains safe and controlled. This statement follows reports of escalating tensions in the Gulf region, which could potentially affect shipping traffic in the Strait of Hormuz, a crucial maritime artery for global trade.
Although the majority of APIs in Indonesia are still imported, the Head of BPOM RI, Dr. Apt. Penny K. Lukito, M.Sc., emphasized in a press conference today that comprehensive mitigation measures have been implemented over the past few years. “In 2026, we have built a more robust resilience system. Lessons learned from previous crises have spurred us to accelerate diversification and self-sufficiency efforts,” Dr. Penny stated.
Diversification of Sources and Strengthening Domestic Upstream Industry
One of BPOM's main strategic pillars is the diversification of API import origins. Based on current data, Indonesia is no longer overly reliant on one or two primary supplier countries. “We have expanded our import network to various countries across Asia, Europe, and even Latin America. This minimizes risk in case of disruption from a single region,” Dr. Penny explained.
Furthermore, the government continues to encourage an increase in domestic upstream pharmaceutical industry capacity. Incentive programs and investment facilities have attracted more industry players to produce APIs in Indonesia. Estimates suggest that by the end of 2026, at least 20% of essential API needs will be met by domestic production, a significant increase from five years ago. “This is not just about quantity, but also quality and innovation. We ensure that domestically produced APIs meet international standards,” added a Ministry of Health official also present.
Strategic Reserves and Global Partnerships
BPOM also affirmed the existence of strategic API reserves managed centrally and distributed across several locations to anticipate unforeseen events. These reserves are designed to meet national needs for a certain period, allowing the government and industry time to find alternative solutions if global supplies are significantly disrupted.
Moreover, Indonesia actively fosters strategic partnerships with other pharmaceutical-producing countries and international organizations to ensure smooth logistical flows and share vital information related to global supply chains. “Dialogue and collaboration are key. We continuously coordinate with regional and global partners to mitigate risks together,” said a representative from the Indonesian Pharmaceutical Association (GPFI) who attended the event.
With these proactive measures, BPOM RI believes that the supply of essential medicines for the Indonesian people will remain secured, providing peace of mind amidst the constantly changing global dynamics.
❓ Frequently Asked Questions
Why is the Strait of Hormuz important for Indonesia's drug supply?
The Strait of Hormuz is a vital shipping lane connecting major pharmaceutical raw material producers in Asia with global markets, including Indonesia. Disruptions in this strait can affect delivery times and logistics costs.
How does BPOM ensure supply remains secure if the Strait of Hormuz is closed?
BPOM implements strategies to diversify import sources, promote domestic raw material production, and maintain strategic reserves of pharmaceutical raw materials to anticipate disruptions in shipping routes like the Strait of Hormuz.
Will this geopolitical tension affect drug prices in Indonesia?
BPOM, along with the government, continuously monitors price stability. With diversification strategies and increased domestic production, efforts are being made to minimize the impact of price increases due to global supply chain disruptions.
